What, what do you think? Uh-

I don't think so.

I think now, uh, we have these, uh, powerful, safe, uh, very, uh, solid, uh, proof drugs with very potent clinical trials.

So I think we should, uh, uh, use them and increase our real, real-life experience.

There is also another, uh, molecule, which is the cKIT inhibitor, rasovolimab, with has also very interesting results reported in, in the meeting.

So, um, I think and also, uh, it's a very important, uh, mechanistic point, which is that D-dimer increases because there is, uh, this, uh, action of, of, of, um, plasmin, but is on in the extra vascular, uh, late.

So, and, uh, this buffering heparin, uh, believes on a coagulation pathway intravascular.

Um, do you make a distinction if you see these patients, treat these patients?